Forth Therapeutics, focused on developing precision therapeutics for fibrosis, has launched with backing from Sofinnova Partners and Old College Capital, leveraging advanced research and technology for rapid growth.

Target Overview

Forth Therapeutics (Forth Tx) is an innovative biotechnology company focused on developing next-generation precision therapeutics specifically for fibrosis. The company has its headquarters in both Edinburgh and Cambridge and was founded based on cutting-edge research conducted by Professor Neil Henderson, a distinguished expert in fibrosis and tissue regeneration. Under the leadership of CEO Alex Leech, a proven entrepreneur and Partner at Sofinnova Partners, Forth Tx aims to address significant unmet medical needs associated with fibrotic conditions.

The company's platform leverages advanced omics technology to enhance drug discovery and development, concentrating on key fibrosis pathways affecting multiple organ systems. Forth Tx's portfolio includes three promising assets designed to combat fibrosis, supported by one of the world's most extensive databases of single-cell human liver disease, which fosters accelerated development of precision therapies.

Industry Overview

The biotechnology sector in the United Kingdom has witnessed substantial growth over the past few years, primarily driven by advancements in genomics, personalized medicine, and an increased focus on precision therapeutics. The UK is home to numerous research instituti